Business Wire

CQN-ALTER-DOMUS

10.5.2022 11:48:12 CEST | Business Wire | Press release

Share
CORRECTING and REPLACING Alter Domus Launches Industry-Leading ESG Reporting Solution for Alternative Investment Managers

Third bullet in the body of the release should read: "Tailored benchmarking against peers and operational support" (instead of "Tailored benchmarking against peers and operational advisory")

The updated release reads:

ALTER DOMUS LAUNCHES INDUSTRY-LEADING ESG REPORTING SOLUTION FOR ALTERNATIVE INVESTMENT MANAGERS

Fund administrator unveils comprehensive and innovative ESG solution that provides regulatory and signatory support for clients

Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has launched an industry-leading Environmental, Social & Governance (ESG) reporting solution.

Despite a lack of standardized ESG models available, demand for ESG data is booming.1 This trend has placed additional strain on alternatives managers who are increasingly fielding ESG data requests from investors, regulators, and non-governmental organizations without a clear directive on how to report or share this data.

Designed specifically for alternative assets, Alter Domus’ ESG Reporting Solution is a cloud-based digital platform that provides comprehensive, tailored reports for clients that collect, store, and disseminate corporate ESG data. Alter Domus’ ESG Reporting Solution will be accessible through an online, user-friendly portal that ensures secure access and management of client data.

Other features of Alter Domus’ ESG Reporting Solution include:

  • Scoring and ratings for a fund or portfolio based on internationally recognized standards
  • Data analysis that can be shared with stakeholders, including regulators for disclosure, compliance, and other reporting purposes
  • Tailored benchmarking against peers and operational support

“Today’s announcement underscores Alter Domus’ commitment to developing and offering the most innovative products that our clients need at a global scale,” said Alex Traub, Chief Commercial Officer. “ESG has become an important part of investment philosophies for investors at every level, and we expect this trend to continue even further as ESG becomes more standardized and mainstream with alternative managers.”

“We have heard from our clients globally about the need for a standardized ESG reporting framework and solution that can be integrated across all of their operations seamlessly,” said Antonis Anastasiou, Managing Director of the Alter Domus Management Company S.A. “We worked to develop this solution that helps our clients not only navigate the complexities of ESG regulation, but to also provide their own investors with the types of reporting they need.”

For its part, and as a growing organization with an increasingly global footprint, Alter Domus ensures that ESG factors are considered as standard practice in all strategic business planning and decision making. Further, Alter Domus is a signatory of the United Nations-supported Principles for Responsible Investment, and aligned with The World Economic Forum (WEF) Measuring Stakeholder Capitalism; Towards Common Metrics and Consistent Reporting of Sustainable Value Creation framework.

Over the last 12 months, Alter Domus has seen increasing demand for alternative investments, particularly in Europe and the United States. Having doubled their assets under administration in that time, Alter Domus is at the forefront of delivering timely, technology-driven solutions to alternative asset managers, lenders, and asset owners globally.

About Alter Domus

Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com .

____________________
1 Opimas Research: http://www.opimas.com/research/547/detail/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye